WebJun 17, 2024 · June 17 (Reuters) - Drugmaker Merck & Co is considering buying cancer-focused biotech company Seagen Inc , the Wall Street Journal reported on Friday, citing people familiar with the matter. WebMar 5, 2024 · The news came weeks after Seagen -linked M&A chatter quietened last year as the company added a new CEO amid reports that pricing disputes ended Merck's bid …
Merck, Seagen Talks Heat Up Under Cloud of Regulatory Scrutiny
WebJul 7, 2024 · Merck & Co is in advanced talks to buy Seagen in a deal that could value the cancer biotech at $40 billion or more, according to a report Wednesday. WebJul 15, 2024 · Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to ... liberty mutual online chat
Merck Has Good Reason to Buy a Cancer-Drug Biotech Seagen
Merck has one of the premier oncology franchises in the industry and sells $17 billion of industry-leading cancer drug Keytruda. The drug is approved for at least 14 different types of cancer, and its sales just keep growing. Year-over-year revenue grew 26% in the second quarter. But Keytruda's patents expire in 2028, … See more Rumors have been circulating ever since The Wall Street Journalreported on the potential merger earlier in the summer. But the companies themselves have remained silent, even after the late July verdict in Seagen's lawsuit … See more Merck doesn't necessarily need to own Seagen in order to benefit from its technology. In fact, the two companies already have several ongoing collaborations. The … See more WebMerck is now in advanced talks to buy Seagen for roughly $40 billion, according to reports that sent SGEN stock higher Thursday. Two major cancer players are reportedly … WebJun 17, 2024 · Biopharma giant Merck is considering an acquisition of Seagen, the Seattle area’s biggest biotech company, according to a report in the Wall Street Journal Friday. liberty mutual olympia wa